ArticleJournal of assisted reproduction and genetics2026
Perioperative safety of emergency ovarian tissue cryopreservation for fertility preservation in hematological patients prior to hematopoietic stem cell transplantation.
Article in Journal of assisted reproduction and genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveHematological patients constitute a key group for fertility preservation, but the surgical risk of emergency ovarian tissue cryopreservation (OTC) before hematopoietic stem cell transplantation (HSCT) is unclear. This study investigates the perioperative safety of emergency OTC management in hematological patients prior to HSCT, and explores the correlation between perioperative treatment, surgical complications, and disease type. Design a single-center retrospective study.
methodsA single-center retrospective analysis was conducted on 67 hematologic patients (non-neoplastic: aplastic anemia, Fanconi anemia, thalassemia; neoplastic: myelodysplastic syndromes, acute lymphocytic leukemia, acute mixed leukemia, acute myeloid leukemia, lymphoma) who underwent emergency OTC before HSCT (January 2023-December 2025). Perioperative management and complications were analyzed, with logistic regression employed to assess the correlation between hematological disease type and perioperative complication occurrence.
resultsCompared with the neoplastic group, the non-neoplastic group had a significantly higher incidence of mild infections (21.43% vs. 0%; p < 0.05). No significant differences were observed in perioperative bleeding (5 vs. 10, p = 0.319) or prolonged hospitalization (5 vs. 6, p = 0.925), both of which were infrequent. The non-neoplastic group also showed significantly lower perioperative blood counts (p < 0.05). Accordingly, these patients required more hematologic support during the perioperative period, with higher rates of red blood cell transfusion (80.95% vs. 28.00%; p < 0.01) and platelet transfusion (90.48% vs. 12.00%; p < 0.01). Logistic regression confirmed a strong association between non-neoplastic hematologic disorders and the need for perioperative red blood cell and platelet transfusion but showed no link with hospitalization duration (p = 0.296).
conclusionWith active perioperative management, patients undergoing emergency OTC prior to HSCT had a low incidence of adverse outcomes. Nevertheless, perioperative care for non-neoplastic patients warrants increased attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.